CD19 and B-cell non-Hodgkin lymphoma: Although the initial clinical evaluation of CAR-T cells focused on B cell non-Hodgkin’s lymphoma (B-NHL) (Kochenderfer et al., 2010; Till et al., 2008), the most striking outcomes have been obtained in B-ALL by targeting CD19, a B cell-lineage antigen expressed on the surface of normal B cells and many malignant B cells (Scheuermann and Racila, 1995; Depoil et al., 2008).